A Study of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents

What Was Tested

In this phase 3 trial, researchers set out to test Ecnoglutide.

It had four arms (groups): one (experimental), one (experimental), one (experimental) and placebo (placebo comparator).

Once weekly.

Once weekly.

Once weekly.

The registry classes the interventions as drug.

More on the Plan

In this study, eligible participants will be randomized into one of the three cohorts in a 3:1 ratio to receive either once-weekly subcutaneous Ecnoglutide injection or placebo, for up to 52 weeks.

Who Took Part

192 planned participants were the target.

It was open to people of any sex aged from 12 years up to 17 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

The full record lists 2 inclusion and 6 exclusion criteria; among the exclusions: pre-adolescent participants (tanner phase 1);; known secondary obesity, including but not limited to that resulting from: hypercortisolism (e.g. cushing's syndrome), pituitary or hypothalamic lesions, or monogenic obesity, etc.;; diagnosis with any type of diabetes;.

How the Study Was Run

Design: randomized, parallel-group and triple-blind.

Random assignment meant chance, not the researchers, decided who got Ecnoglutide and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

As a double-blind Ecnoglutide study, the assignments were hidden from both participants and investigators until the end.

Those kept unaware of assignments: participant, care provider and investigator.

It started in 2026-10-31 with completion listed for 2028-06-08.

It ran at 1 site in China.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Percent change in Body Mass Index (BMI) (time frame: Baseline, week 40).

It also tracked 15 secondary outcomes, for example Change in BMI, Change in body weight, Change in Glycated Hemoglobin (HbA1c), Change in Fasting Plasma Glucose (FPG), Change in Fasting Insulin and Change in Homeostasis Model Assessment 2 - Insulin Resistance (HOMA2-IR).

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Ecnoglutide in 192 people.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Ecnoglutide compound page, all human trials.